tiprankstipranks
Trending News
More News >
Avalo Therapeutics (AVTX)
NASDAQ:AVTX
Advertisement

Avalo Therapeutics (AVTX) AI Stock Analysis

Compare
1,006 Followers

Top Page

AVTX

Avalo Therapeutics

(NASDAQ:AVTX)

Select Model
Select Model
Select Model
Neutral 52 (OpenAI - 4o)
Rating:52Neutral
Price Target:
$11.50
▲(2.22% Upside)
The overall stock score for Avalo Therapeutics is primarily impacted by its poor financial performance, characterized by declining revenues and persistent losses. Despite positive technical indicators suggesting bullish momentum, the negative valuation metrics due to ongoing losses weigh heavily on the stock's attractiveness.
Positive Factors
Debt Elimination
Eliminating total debt improves financial flexibility and reduces interest expenses, allowing Avalo Therapeutics to focus resources on R&D and strategic growth.
Equity Improvement
Improved equity indicates better financial health and can enhance investor confidence, providing a stronger foundation for future financing and growth opportunities.
Proprietary Platform
Avalo's proprietary platform for rare diseases offers a competitive edge in niche markets, potentially leading to successful drug developments and partnerships.
Negative Factors
Declining Revenue
Significant revenue decline indicates challenges in product commercialization and market penetration, affecting long-term sustainability and growth prospects.
Negative Cash Flow
Persistent negative cash flow suggests operational inefficiencies and reliance on external financing, which may not be sustainable, impacting long-term viability.
Negative Profitability
Consistent negative profitability reflects structural issues in cost management and revenue generation, hindering Avalo's ability to achieve financial stability.

Avalo Therapeutics (AVTX) vs. SPDR S&P 500 ETF (SPY)

Avalo Therapeutics Business Overview & Revenue Model

Company DescriptionAvalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
How the Company Makes MoneyAvalo Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company may earn income from product sales once its candidates receive regulatory approval and are launched in the market. Additionally, Avalo could engage in strategic partnerships or collaborations with larger pharmaceutical companies, which may provide upfront payments, milestone payments, and royalties on sales of partnered products. Government grants and research funding can also contribute to its revenue, especially during the early stages of product development. Overall, the company’s financial health is heavily dependent on the successful advancement of its drug candidates through clinical trials and subsequent market introduction.

Avalo Therapeutics Financial Statement Overview

Summary
Avalo Therapeutics faces significant financial challenges, with declining revenues, persistent losses, and negative cash flow. Despite improvements in equity and debt elimination, the company's inability to generate positive cash flow and profits suggests substantial financial instability.
Income Statement
25
Negative
Avalo Therapeutics has experienced a significant decline in revenue over the years, with the most recent annual revenue dropping to $441,000 from $1,924,000 the previous year. The company also shows negative gross profit and net income over multiple years, indicating ongoing operational challenges. Additionally, the net profit margin is consistently negative, reflecting broader profitability issues.
Balance Sheet
40
Negative
The company's balance sheet shows a high equity ratio, primarily due to the elimination of total debt in the most recent year. However, the return on equity remains negative due to ongoing net losses. The stockholders' equity has improved significantly from negative to positive over the past year, which is a positive sign, but the lack of revenue growth remains concerning.
Cash Flow
30
Negative
Avalo Therapeutics demonstrates negative free cash flow consistently, indicating cash flow challenges. The operating cash flow to net income ratio is also negative, highlighting inefficiencies in translating operational activities into cash flow. Although financing activities have supported operations in previous years, the sustainability of this approach is uncertain given ongoing losses.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue441.00K441.00K1.92M18.05M5.40M6.70M
Gross Profit934.00K807.00K640.00K14.62M3.91M6.40M
EBITDA-61.22M-68.34M-23.29M-37.29M-80.50M-45.45M
Net Income-46.22M-35.13M-31.54M-41.66M-84.35M-64.38M
Balance Sheet
Total Assets126.58M150.73M20.99M33.37M80.21M43.76M
Cash, Cash Equivalents and Short-Term Investments113.28M134.55M7.42M13.17M54.59M18.92M
Total Debt2.68M568.00K537.00K19.42M32.83M426.35K
Total Liabilities22.01M17.70M13.69M44.28M57.13M19.19M
Stockholders Equity104.57M133.03M7.30M-10.91M23.08M24.56M
Cash Flow
Free Cash Flow-47.42M-49.06M-30.84M-26.85M-71.00M-40.60M
Operating Cash Flow-47.42M-49.06M-30.68M-26.75M-70.89M-40.54M
Investing Cash Flow-70.86M356.00K-133.00K-95.00K-113.00K11.13M
Financing Cash Flow67.24M175.85M25.04M-14.70M106.76M44.78M

Avalo Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price11.25
Price Trends
50DMA
9.07
Positive
100DMA
6.76
Positive
200DMA
7.06
Positive
Market Momentum
MACD
0.72
Positive
RSI
61.35
Neutral
STOCH
77.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVTX, the sentiment is Positive. The current price of 11.25 is above the 20-day moving average (MA) of 10.73, above the 50-day MA of 9.07, and above the 200-day MA of 7.06, indicating a bullish trend. The MACD of 0.72 indicates Positive momentum. The RSI at 61.35 is Neutral, neither overbought nor oversold. The STOCH value of 77.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AVTX.

Avalo Therapeutics Risk Analysis

Avalo Therapeutics disclosed 64 risk factors in its most recent earnings report. Avalo Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Avalo Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$153.88M-90.25%-45.35%96.80%
47
Neutral
134.58M-1.38-82.53%-26.57%
42
Neutral
107.76M-1.71
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AVTX
Avalo Therapeutics
11.25
1.90
20.32%
DOMH
Dominari Holdings
7.28
5.56
323.26%
RENB
Renovaro Biosciences
0.17
-0.31
-64.58%
KRON
Kronos Bio
0.88
-0.07
-7.37%
PYXS
Pyxis Oncology
2.19
-1.53
-41.13%
ANRO
Alto Neuroscience, Inc.
4.11
-7.89
-65.75%

Avalo Therapeutics Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Avalo Therapeutics Highlights Potential of AVTX-009 in HS
Positive
Jun 20, 2025

On June 20, 2025, Avalo Therapeutics released an updated investor presentation highlighting the potential of its lead compound, AVTX-009, which shows promise in treating hidradenitis suppurativa (HS) with a higher affinity and longer half-life compared to existing treatments. The Phase 2 LOTUS trial for AVTX-009 is currently enrolling, with topline data expected by mid-2026, and the HS market is projected to grow significantly, offering substantial opportunities for Avalo and its stakeholders.

Executive/Board ChangesBusiness Operations and Strategy
Avalo Therapeutics Appoints Dr. Rita Jain to Board
Positive
Jun 18, 2025

On June 17, 2025, Avalo Therapeutics appointed Dr. Rita Jain to its Board of Directors, bringing her extensive experience in biopharmaceutical development and regulatory affairs. This strategic addition aims to bolster Avalo’s efforts in advancing its lead asset, AVTX-009, currently in a Phase 2 trial for hidradenitis suppurativa, and aligns with the company’s broader development strategy. The Board also approved a revised compensation plan for non-employee directors to attract and retain qualified members, effective the same day.

Executive/Board ChangesShareholder Meetings
Avalo Therapeutics Holds 2025 Annual Meeting
Neutral
Jun 17, 2025

Avalo Therapeutics held its 2025 Annual Meeting on June 17, 2025, where stockholders voted on several key proposals. The meeting saw a high participation rate with approximately 90% of shares present or represented by proxy. During the meeting, eight nominees were elected to the Board, a ‘Say-on-Pay’ resolution was approved, and Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 18, 2025